Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BENEBIOSIS CO., LTD. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to a distinct examiner working within 1 distinct art unit. The concentration of the portfolio shows the company's current patent prosecution focus. Prosecution within Biotechnology & Pharmaceuticals involves the specific examination standards of that field.
DICKINSON, PAUL W is the busiest examiner for this portfolio. This individual is responsible for the busiest examiner pending office action. This examiner handles the workload of the company's current prosecution in this technology area. The examiner's role is a feature of the current portfolio status.
The presence of a distinct art unit indicates that the technical reviews occur within a specific administrative group. Practitioners can focus their strategy on the requirements of the examiner assigned. This profile reflects a portfolio with a point of interaction with the patent office at this time. The alignment of the pending matter within this specific technology area defines the current interaction with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16069972 | COMPOSITION FOR INCREASING EXPRESSION OF PGC-1alpha | DICKINSON, PAUL W | 1618 | §112 | Non-Final OA | — | Pending | Jul 13, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBENEBIOSIS CO., LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul W Dickinson has the most, with 1 of BENEBIOSIS CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
